)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aquestive Therapeutics
Aquestive Therapeutics (AQST) investor relations material
Aquestive Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Anaphylm’s NDA resubmission was accepted as a Class 2 response; the FDA PDUFA goal date is March 16, 2027, with U.S. launch preparations continuing, subject to approval.
International filing plans target Health Canada in Q4 2026 and the EU in Q1 2027.
Eton received exclusive U.S. Libervant commercialization rights in October; the agreement includes $10 million upfront and contingent milestones and royalties.
Financial highlights
Q3 2026 revenue was $7.6 million versus $12.8 million year over year, mainly due to lower Suboxone orders; manufacture and supply revenue was $6.7 million versus $11.5 million.
9M revenue rose 14% to $35.8 million from $31.5 million, including $5 million of Zevra-related royalty revenue; manufacturing and supply revenue was $27.4 million versus $28.2 million.
Q3 net loss was $16.5 million, or $0.13 per share, versus $15.4 million, or $0.14 per share; 9M net loss narrowed to $47.4 million from $51.9 million.
Q3 adjusted EBITDA loss was $12.2 million versus $8.6 million; 9M adjusted EBITDA loss narrowed to $19.2 million from $35.5 million.
Q3 operating loss was $14.5 million versus $11.5 million; 9M operating loss narrowed to $26.9 million from $42.2 million.
Outlook and guidance
FY 2026 guidance was maintained at revenue of $46 million-$50 million and non-GAAP adjusted EBITDA loss of $30 million-$35 million.
Year-end 2026 cash and cash equivalents are expected to exceed $70 million, including Eton’s $10 million October upfront payment and excluding contingent RTW and Oaktree funding.
Anaphylm launch preparations target Q1 2027, subject to FDA approval; the PDUFA goal date is March 16, 2027.
Additional AQST-108 clinical work is expected to begin in Q1 2027; Health Canada and EU filings are planned for Q4 2026 and Q1 2027, respectively.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aquestive Therapeutics
- Anaphylm is set for launch, targeting unmet needs with strong clinical and commercial readiness.AQST
H.C. Wainwright 28th Annual Global Investment Conference - Anaphylm's rapid, user-friendly delivery and strong clinical profile position it for major market impact.AQST12th Annual Cantor Fitzgerald Global Healthcare Conference
- Q2 2026 revenue up 38% to $13.8M; Anaphylm NDA resubmission and launch prep on track.AQSTQ2 2026
- Resale registration for 230,271 warrant shares tied to Oaktree credit facility, exercisable at $4.18.AQSTRegistration filing
- FDA progress, global expansion, and all proposals passed with strong shareholder support.AQSTAGM 2026
- Q1 2026 revenue rose 66% to $14.4M, net loss narrowed, and key regulatory milestones advanced.AQSTQ1 2026
- Virtual annual meeting to vote on directors, executive pay, and auditor ratification.AQSTProxy filing
- AQST-108, a topical epinephrine gel for alopecia areata, targets a post-2028 launch.AQSTInvestor Day 2024
- Q1 2025 revenue fell 28% as focus shifted to Anaphylm launch and Libervant sales paused.AQSTQ1 2025
Next Aquestive Therapeutics earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
Aquestive Therapeutics
Next Aquestive Therapeutics earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aquestive Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies using its proprietary drug delivery technology. The company specializes in orally administered films designed to improve the efficacy, safety, and convenience of treatments for patients with central nervous system disorders and other medical conditions. Aquestive also partners with other pharmaceutical companies to develop unique drug formulations. The company is headquartered in Warren, New Jersey, and its shares are listed on the NASDAQ.